Indegene Limited (NSE:INDGN)
India · Delayed Price · Currency is INR 572.65
+0.45 (0.08%)
Aug 14, 2025, 3:30 PM IST
Indegene Revenue
Indegene had revenue of 7.61B INR in the quarter ending June 30, 2025, with 12.46% growth. This brings the company's revenue in the last twelve months to 29.24B, up 9.97% year-over-year. In the fiscal year ending March 31, 2025, Indegene had annual revenue of 28.39B with 9.64% growth.
Revenue (ttm)
29.24B
Revenue Growth
+9.97%
P/S Ratio
4.70
Revenue / Employee
7.03M
Employees
4,158
Market Cap
137.44B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 28.39B | 2.50B | 9.64% |
| Mar 31, 2024 | 25.90B | 2.84B | 12.29% |
| Mar 31, 2023 | 23.06B | 6.41B | 38.54% |
| Mar 31, 2022 | 16.65B | 6.84B | 69.76% |
| Mar 31, 2021 | 9.81B | 3.37B | 52.36% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Divi's Laboratories | 96.52B |
| Cipla | 274.80B |
| Apollo Hospitals Enterprise | 217.94B |
| Mankind Pharma | 129.10B |
| Zydus Lifesciences | 232.42B |
| Fortis Healthcare | 80.94B |
| Aurobindo Pharma | 320.25B |